Yik Zhi Kum

DECIPHERING THE PUZZLE

Yik Zhi Kum, Siti Nabilah Atiqah Othman, Adilah Zulaikha Abd Latib, Orie Ng

INTRODUCTION/BACKGROUND GLP-1 agonists are crucial treatments for type 2 diabetes and obesity due to their positive impact on glucose control and weight. However, concerns have arisen about their potential to cause pre-renal acute kidney injury (AKI), typically attributed to gastrointestinal side effects. …

sa, my (code pays fourni par la source)

UNVEILING SIADH

Siti Nabilah Atiqah Othman, Yik Zhi Kum, Adilah Zulaikha Abd Latib, Orie Ng

INTRODUCTION/BACKGROUNDHyponatremia is an uncommon complication of abiraterone treatment with an incidence rate of 0.4%-5%. Syndrome of inappropriate antidiuretic hormone secretion (SIADH) as a complication of abiraterone therapy is even rarer, and to our knowledge, this is the first-ever report on abirateroneinduced SIADH …

THYROID FUNCTION ABNORMALITIES

A. Latib, Yik Zhi Kum, Soufiane Ben Othman, Orie Ng

INTRODUCTION/BACKGROUNDSubclinical hyperthyroidism presents with low or undetectable levels of thyroid stimulating hormone (TSH), alongside normal levels of free thyroid hormones (fT4 and fT3). While certain individuals may not show any symptoms, others may experience hyperthyroid symptoms like palpitations, weight loss, and heat …

Efficacy of Ivermectin Treatment on Disease Progression Among Adults With Mild to Moderate COVID-19 and Comorbidities

Steven Chee Loon Lim, Chee Peng Hor, Kim Heng Tay, Anilawati Mat Jelani et autres

Importance: Ivermectin, an inexpensive and widely available antiparasitic drug, is prescribed to treat COVID-19. Evidence-based data to recommend either for or against the use of ivermectin are needed. Objective: To determine the efficacy of ivermectin in preventing progression to severe disease among …

my (code pays fourni par la source)

Efficacy of Early Treatment With Favipiravir on Disease Progression Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19): A Randomized, Open-Label Clinical Trial

Chuan Huan Chuah, Ting Soo Chow, Chee Peng Hor, Joo Thye Cheng et autres

BACKGROUND: The role of favipiravir in preventing disease progression in coronavirus disease 2019 (COVID-19) remains uncertain. We aimed to determine its effect in preventing disease progression from nonhypoxia to hypoxia among high-risk COVID-19 patients. METHODS: This was an open-label, randomized clinical trial …

my, us (code pays fourni par la source)